bpc-157 interstitial cystitis pilot as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Effect of BPC-157 on Symptoms
Description
Presse Medicale 2012;41:8958
Total amount of yielded PRP was approximately 6 ml
This fragment-based approach is what differentiates AOD-9604 from GHRH analogs such as Tesamorelin, which act upstream in the pituitary rather than directly on metabolic pathways
Management: adjusting dose/frequency, topical treatments, or in some cases a dermatologist referral
